Erratum (DOI:10.1016/j.transproceed.2006.10.110);Basiliximab Induction in Adult Liver Transplant Recipients With 93% Rejection-Free Patient and Graft Survival at 24 Months

Transplantation Proceedings

Volumn 38, Issue 10, 2006, Pages 3633-3635

  Ramirez, C B ^a   Doria, C ^a   DiFrancesco, F ^a   Iaria, M ^a   Kang, Y ^a   Marino, I R ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CD3 ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; STEROID; TACROLIMUS;

ADULT; ARTICLE; BACTEREMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; FEMALE; FOLLOW UP; FUNGEMIA; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAHEPATIC CHOLESTASIS; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; SURVIVAL RATE;

EID: 33845421121     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.03.041     Document Type: Erratum

References (10)

1. Nashan B., Moore R., Amlot P., et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350 (1997) 1193
2. Kahan B.D., Rajagopalan P.R., Hall M., and United States Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 67 (1999) 276
3. Ponticelli C., Yussim A., Cambi V., et al., Simulect Phase IV Study Group. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 72 (2001) 1261
4. Lawen J.G., Davies E.A., Mourad G., et al., Simulect International Study Group. Randomized, double blind study of immuno-prophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 75 (2003) 37
5. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13 (1991) 372
6. Brennan D.C. Action, efficacy and toxicities: polyclonal anti-lymphocyte antibodies. In: Norman D.J., and Turka L.A. (Eds). Primer on Transplantation. Ed. 2 (2001), American Society of Transplantation, Mt. Laurel, NJ 152
7. Singh N., Gayowski T., Wannstedt C.F., et al. Interferon alpha therapy for hepatitis C virus recurrence after liver transplantation: long term response with maintenance therapy. Clin Transplant 10 (1996) 348
8. Gayowski T., Singh N., Marino I.R., et al. Hepatitis C genotypes in liver transplant recipients: impact on post-transplant recurrence, infections, response to interferon-α therapy and outcome. Transplantation 64 (1997) 422
9. Schluger L.K., Sheiner P.A., Thung S.N., et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 23 (1996) 971
10. Dickson R.C., Caldwell S.H., Ishitani M.B., et al. Clinical and histological patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation 61 (1996) 701